Global HIFU Adoption Will Open New Markets

Key Takeaways

• Rapid adoption of minimally invasive HIFU technology and improved reimbursement is driving market expansion, higher procedure revenue, and deeper hospital network penetration.
  
• New therapeutic indications, growing recurring revenue, and strengthened global operations position EDAP for sustained multi-year growth and greater earnings visibility.
  
• Revenue growth is threatened by slowing HIFU adoption, operating losses, declining noncore sales, regulatory risk, and rising competition from alternative urology technologies.

Catalysts

Develops, manufactures, promotes, and distributes minimally-invasive medical devices for urology based upon proprietary ultrasound technology in Asia, France, the United States, and internationally.

• Rapid global adoption of the Focal One HIFU platform, driven by compelling new clinical evidence (HIFI and FARP studies) and rising patient and physician preference for minimally invasive, organ-sparing cancer therapies, strongly positions EDAP to benefit from an expanding addressable market, supporting substantial future revenue growth and installed base expansion.
  
• Enhanced reimbursement rates and new CPT codes for HIFU procedures-including proposed 2026 CMS increases and expanded coverage for benign prostatic hyperplasia and prostate cancer-are set to boost hospital adoption, improve patient access, and directly increase the company's revenue per procedure and net margins.
  
• Expansion into new therapeutic areas, such as the recent CE mark and initial commercialization of HIFU for endometriosis in Europe, leverages the existing technology platform and opens large, new patient populations, paving the way for incremental revenue streams and better earnings visibility.
  
• Increased recurring revenue from disposables and service contracts linked to the growing installed base of Focal One systems is already resulting in higher gross and net margins, and this trend should accelerate as adoption deepens across major hospital networks and geographies.
  
• Strengthened balance sheet (pending strategic €36M financing), expanded commercial teams in key global regions, and US regulatory status upgrades position EDAP to capitalize on long-term demographic trends (aging population, rising cancer incidence), further diversifying revenue and sustaining multi-year growth in revenue and profitability.

EDAP TMS Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming EDAP TMS's revenue will grow by 10.5% annually over the next 3 years.
• Analysts are not forecasting that EDAP TMS will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate EDAP TMS's profit margin will increase from -41.7% to the average US Medical Equipment industry of 11.8% in 3 years.
• If EDAP TMS's profit margin were to converge on the industry average, you could expect earnings to reach $11.8 million (and earnings per share of $0.39) by about July 2029, up from -$30.9 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 27.6x on those 2029 earnings, up from -6.6x today. This future PE is greater than the current PE for the US Medical Equipment industry at 27.5x.
• Analysts expect the number of shares outstanding to decline by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 8.16%, as per the Simply Wall St company report.

Risks

• The dramatic slowdown in HIFU procedure growth from 30%+ to mid-single digits, partially attributed to regional payer/Medicare Advantage issues, exposes risk that insurance reimbursement challenges or payer pushback could persist or worsen, directly limiting future procedure adoption and dampening revenue growth.
  
• Ongoing operating losses (€5.6 million net loss in Q2, with increasing losses over the first half of 2025 compared to last year) despite gross margin improvements indicate EDAP TMS's continued need for high investment to fuel growth, raising the risk that heavy operating costs or an inability to achieve scale could delay or prevent a profitable long-term business model, affecting earnings and net margins.
  
• Sharp declines in noncore ESWL and distribution revenue (down 31.2% YoY in Q2) expose the company to heightened revenue concentration and vulnerability to disruptions in HIFU trends; if demand for HIFU systems weakens, overall company sales could fall sharply, increasing earnings volatility and business risk.
  
• EDAP remains reliant on continued favorable regulatory and reimbursement frameworks (e.g., CMS rates, pending final rules, key clinical data), and future regulatory or reimbursement delays or negative changes (such as lower payment rates, more restrictive coverage, or additional evidence requirements for new indications) could slow time-to-market or reduce addressable market, hurting long-term revenue and margins.
  
• Intensifying competition from other ablative and minimally invasive urology technologies (including TULSA, IRE, and emerging modalities) and the risk of technological obsolescence-especially if EDAP's product development does not keep pace-could lead to price pressure, customer attrition, and shrinking market share, jeopardizing revenue and future profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $8.5 for EDAP TMS based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $15.0, and the most bearish reporting a price target of just $3.0.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $99.9 million, earnings will come to $11.8 million, and it would be trading on a PE ratio of 27.6x, assuming you use a discount rate of 8.2%.
• Given the current share price of $5.43, the analyst price target of $8.5 is 36.1% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.